- Home
- ADCT vs HYI Comparison
ADCT vs HYI Comparison
Compare ADCT & HYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- HYI
- Stock Information
- Founded
- ADCT 2011
- HYI 2010
- Country
- ADCT Switzerland
- HYI United States
- Employees
- ADCT N/A
- HYI N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- HYI Investment Managers
- Sector
- ADCT Health Care
- HYI Finance
- Exchange
- ADCT Nasdaq
- HYI Nasdaq
- Market Cap
- ADCT 241.0M
- HYI 269.0M
- IPO Year
- ADCT 2020
- HYI N/A
- Fundamental
- Price
- ADCT $2.78
- HYI $11.90
- Analyst Decision
- ADCT Strong Buy
- HYI
- Analyst Count
- ADCT 6
- HYI 0
- Target Price
- ADCT $7.80
- HYI N/A
- AVG Volume (30 Days)
- ADCT 937.9K
- HYI 50.6K
- Earning Date
- ADCT 08-05-2025
- HYI 01-01-0001
- Dividend Yield
- ADCT N/A
- HYI 9.59%
- EPS Growth
- ADCT N/A
- HYI N/A
- EPS
- ADCT N/A
- HYI N/A
- Revenue
- ADCT $75,817,000.00
- HYI N/A
- Revenue This Year
- ADCT $10.65
- HYI N/A
- Revenue Next Year
- ADCT $15.05
- HYI N/A
- P/E Ratio
- ADCT N/A
- HYI N/A
- Revenue Growth
- ADCT 10.49
- HYI N/A
- 52 Week Low
- ADCT $1.05
- HYI $10.99
- 52 Week High
- ADCT $4.13
- HYI $12.24
- Technical
- Relative Strength Index (RSI)
- ADCT 47.62
- HYI 59.64
- Support Level
- ADCT $3.21
- HYI $11.82
- Resistance Level
- ADCT $3.97
- HYI $11.89
- Average True Range (ATR)
- ADCT 0.38
- HYI 0.07
- MACD
- ADCT -0.12
- HYI 0.00
- Stochastic Oscillator
- ADCT 3.43
- HYI 84.00
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.